speb/financial-data huggingface dataset:
RXO balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 51000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 51000000.00
RXO balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 51000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 51000000.00
RXO income_statement (annual, 2025-12-31) — Normalized EBITDA: 108000000.00
RXO income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 19000000.00
RXO income_statement (annual, 2025-12-31) — Normalized Income: -37576000.00
RXO income_statement (quarterly, 2025-12-31) — Normalized Income: -16235294.12
RXO cash_flow (annual, 2025-12-31) — Operating Cash Flow: 51000000.00
RXO cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 7000000.00
RXO income_statement (annual, 2025-12-31) — Operating Income: -7000000.00
RXO income_statement (quarterly, 2025-12-31) — Operating Income: -9000000.00
RXO income_statement (annual, 2025-12-31) — Operating Revenue: 5742000000.00
RXO income_statement (quarterly, 2025-12-31) — Operating Revenue: 1469000000.00
RXO balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 164160000.00
RXO balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 164160000.00
RXO balance_sheet (annual, 2025-12-31) — Other Current Assets: 74000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 74000000.00
RXO balance_sheet (annual, 2025-12-31) — Other Current Borrowings: 17000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Other Current Borrowings: 17000000.00
RXO balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 10000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 10000000.00
RXO balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: -6000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: -6000000.00
RXO income_statement (annual, 2025-12-31) — Other Income Expense: -73000000.00
RXO income_statement (quarterly, 2025-12-31) — Other Income Expense: -33000000.00
RXO balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 453000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 453000000.00
RXO cash_flow (annual, 2025-12-31) — Other Non Cash Items: 11000000.00
RXO cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 4000000.00
RXO balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 24000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 24000000.00
RXO balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 69000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 69000000.00
RXO income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: -1000000.00
RXO income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 0.00
RXO balance_sheet (annual, 2025-12-31) — Other Properties: 238000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Other Properties: 238000000.00
RXO balance_sheet (annual, 2025-12-31) — Payables: 539000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Payables: 539000000.00
RXO balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 936000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 936000000.00
RXO balance_sheet (annual, 2025-12-31) — Preferred Stock: 0.00
RXO balance_sheet (quarterly, 2025-12-31) — Preferred Stock: 0.00
RXO income_statement (annual, 2025-12-31) — Pretax Income: -115000000.00
RXO income_statement (quarterly, 2025-12-31) — Pretax Income: -51000000.00
RXO cash_flow (annual, 2025-12-31) — Purchase Of Business: -10000000.00
RXO cash_flow (quarterly, 2025-12-31) — Purchase Of Business: 0.00
RXO cash_flow (annual, 2025-12-31) — Purchase Of PPE: -59000000.00
RXO cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -16000000.00
RXO balance_sheet (annual, 2025-12-31) — Receivables: 1226000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Receivables: 1226000000.00
RXO income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 4917000000.00
RXO income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 1278000000.00
RXO income_statement (annual, 2025-12-31) — Reconciled Depreciation: 116000000.00
RXO income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 28000000.00
RXO cash_flow (annual, 2025-12-31) — Repayment Of Debt: -535000000.00
RXO cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -96000000.00
RXO cash_flow (annual, 2025-12-31) — Repurchase Of Capital Stock: 0.00
RXO income_statement (annual, 2025-12-31) — Restructuring And Mergern Acquisition: 60000000.00
RXO income_statement (quarterly, 2025-12-31) — Restructuring And Mergern Acquisition: 21000000.00
RXO balance_sheet (annual, 2025-12-31) — Retained Earnings: -384000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -384000000.00
RXO cash_flow (annual, 2025-12-31) — Sale Of PPE: 2000000.00
RXO cash_flow (quarterly, 2025-12-31) — Sale Of PPE: 1000000.00
RXO income_statement (annual, 2025-12-31) — Selling General And Administration: 832000000.00
RXO income_statement (quarterly, 2025-12-31) — Selling General And Administration: 200000000.00
RXO balance_sheet (annual, 2025-12-31) — Share Issued: 164160000.00
RXO balance_sheet (quarterly, 2025-12-31) — Share Issued: 164160000.00
RXO income_statement (annual, 2025-12-31) — Special Income Charges: -72000000.00
RXO income_statement (quarterly, 2025-12-31) — Special Income Charges: -33000000.00
RXO cash_flow (annual, 2025-12-31) — Stock Based Compensation: 29000000.00
RXO cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 7000000.00
RXO balance_sheet (annual, 2025-12-31) — Stockholders Equity: 1541000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 1541000000.00
RXO balance_sheet (annual, 2025-12-31) — Tangible Book Value: -23000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: -23000000.00
RXO income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -9576000.00
RXO income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -3235294.12
RXO income_statement (annual, 2025-12-31) — Tax Provision: -15000000.00
RXO income_statement (quarterly, 2025-12-31) — Tax Provision: -5000000.00
RXO income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.13
RXO income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.10
RXO balance_sheet (annual, 2025-12-31) — Total Assets: 3277000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Total Assets: 3277000000.00
RXO balance_sheet (annual, 2025-12-31) — Total Capitalization: 1928000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 1928000000.00
RXO balance_sheet (annual, 2025-12-31) — Total Debt: 670000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Total Debt: 670000000.00
RXO balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 1541000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 1541000000.00
RXO income_statement (annual, 2025-12-31) — Total Expenses: 5749000000.00
RXO income_statement (quarterly, 2025-12-31) — Total Expenses: 1478000000.00
RXO balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 1736000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 1736000000.00
RXO balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 1960000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 1960000000.00
RXO balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 698000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 698000000.00
RXO income_statement (annual, 2025-12-31) — Total Operating Income As Reported: -79000000.00
RXO income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: -42000000.00
RXO income_statement (annual, 2025-12-31) — Total Unusual Items: -72000000.00
RXO income_statement (quarterly, 2025-12-31) — Total Unusual Items: -33000000.00
RXO income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -72000000.00
RXO income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -33000000.00
RXO balance_sheet (annual, 2025-12-31) — Working Capital: 279000000.00
RXO balance_sheet (quarterly, 2025-12-31) — Working Capital: 279000000.00
RXO income_statement (quarterly, 2026-03-31) — +Operating Expense: 197000000.00
RXO income_statement (quarterly, 2026-03-31) — +Total Revenue: 1425000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 584000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 1216000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -396000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 1934000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -15000000.00
RXO cash_flow (quarterly, 2026-03-31) — Asset Impairment Charge: 4000000.00
RXO income_statement (quarterly, 2026-03-31) — Basic Average Shares: 169104000.00
RXO income_statement (quarterly, 2026-03-31) — Basic EPS: -0.21
RXO cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 18000000.00
RXO cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -17000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 252000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Capital Stock: 2000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 21000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 21000000.00
RXO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 28000000.00
RXO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -17000000.00
RXO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -7000000.00
RXO cash_flow (quarterly, 2026-03-31) — Change In Account Payable: 49000000.00
RXO cash_flow (quarterly, 2026-03-31) — Change In Accrued Expense: -36000000.00
RXO cash_flow (quarterly, 2026-03-31) — Change In Other Current Assets: -27000000.00
RXO cash_flow (quarterly, 2026-03-31) — Change In Payable: 49000000.00
RXO cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: 13000000.00
RXO cash_flow (quarterly, 2026-03-31) — Change In Receivables: 8000000.00
RXO cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -6000000.00
RXO cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: 8000000.00
RXO cash_flow (quarterly, 2026-03-31) — Changes In Cash: 4000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Common Stock: 2000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 1509000000.00
RXO income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 1247000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 367000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Current Assets: 1335000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 70000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Current Debt: 17000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 87000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 1048000000.00
RXO cash_flow (quarterly, 2026-03-31) — Deferred Income Tax: -15000000.00
RXO cash_flow (quarterly, 2026-03-31) — Deferred Tax: -15000000.00
RXO cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 26000000.00
RXO cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 26000000.00
RXO income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 169104000.00
RXO income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.21
RXO income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -36000000.00
RXO income_statement (quarterly, 2026-03-31) — EBIT: -40000000.00
RXO income_statement (quarterly, 2026-03-31) — EBITDA: -14000000.00
RXO cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: 0.00
RXO cash_flow (quarterly, 2026-03-31) — End Cash Position: 22000000.00
RXO cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 28000000.00
RXO cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -24000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: -7000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Goodwill: 1111000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 1553000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 1231000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Gross PPE: 749000000.00
RXO income_statement (quarterly, 2026-03-31) — Gross Profit: 178000000.00
RXO cash_flow (quarterly, 2026-03-31) — Income Tax Paid Supplemental Data: 1000000.00
RXO income_statement (quarterly, 2026-03-31) — Interest Expense: 9000000.00
RXO income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 9000000.00
RXO cash_flow (quarterly, 2026-03-31) — Interest Paid Supplemental Data: 8000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Invested Capital: 1956000000.00
RXO cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -17000000.00
RXO cash_flow (quarterly, 2026-03-31) — Issuance Of Debt: 725000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 182000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 430000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 612000000.00
RXO cash_flow (quarterly, 2026-03-31) — Long Term Debt Issuance: 725000000.00
RXO cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -687000000.00
RXO cash_flow (quarterly, 2026-03-31) — Net Business Purchase And Sale: 0.00
RXO balance_sheet (quarterly, 2026-03-31) — Net Debt: 426000000.00
RXO income_statement (quarterly, 2026-03-31) — Net Income: -36000000.00
RXO income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -36000000.00
RXO income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -36000000.00
RXO income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -36000000.00
RXO income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -36000000.00
RXO cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -36000000.00
RXO income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -36000000.00
RXO income_statement (quarterly, 2026-03-31) — Net Interest Income: -9000000.00
RXO cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: 38000000.00
RXO cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: 38000000.00
RXO income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -9000000.00
RXO cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: -10000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Net PPE: 353000000.00
RXO cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -17000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: -44000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 36000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 36000000.00
RXO income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 6000000.00
RXO income_statement (quarterly, 2026-03-31) — Normalized Income: -21100000.00
RXO cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -7000000.00
RXO cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: 11000000.00
RXO income_statement (quarterly, 2026-03-31) — Operating Income: -19000000.00
RXO income_statement (quarterly, 2026-03-31) — Operating Revenue: 1425000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 164867000.00
RXO balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 98000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Other Current Borrowings: 17000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 10000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: -7000000.00
RXO income_statement (quarterly, 2026-03-31) — Other Income Expense: -21000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 442000000.00
RXO cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 2000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 27000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 63000000.00
RXO income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: -1000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Other Properties: 749000000.00
RXO income_statement (quarterly, 2026-03-31) — Other Special Charges: 11000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Payables: 584000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 951000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Preferred Stock: 0.00
RXO income_statement (quarterly, 2026-03-31) — Pretax Income: -49000000.00
RXO cash_flow (quarterly, 2026-03-31) — Purchase Of Business: 0.00
RXO cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -17000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Receivables: 1216000000.00
RXO income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 1247000000.00
RXO income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 26000000.00
RXO cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -687000000.00
RXO income_statement (quarterly, 2026-03-31) — Restructuring And Mergern Acquisition: 9000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -420000000.00
RXO income_statement (quarterly, 2026-03-31) — Selling General And Administration: 197000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Share Issued: 164867000.00
RXO income_statement (quarterly, 2026-03-31) — Special Income Charges: -20000000.00
RXO cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 7000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 1509000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: -44000000.00
RXO income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -5100000.00
RXO income_statement (quarterly, 2026-03-31) — Tax Provision: -13000000.00
RXO income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.26
RXO balance_sheet (quarterly, 2026-03-31) — Total Assets: 3268000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 1939000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Total Debt: 699000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 1509000000.00
RXO income_statement (quarterly, 2026-03-31) — Total Expenses: 1444000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 1759000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 1933000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 711000000.00
RXO income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -28000000.00
RXO income_statement (quarterly, 2026-03-31) — Total Unusual Items: -20000000.00
RXO income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -20000000.00
RXO balance_sheet (quarterly, 2026-03-31) — Working Capital: 287000000.00
RXRX balance_sheet (annual, 2021-12-31) — Accounts Receivable: 34000.00
RXRX cash_flow (annual, 2021-12-31) — Changes In Account Receivables: 114000.00
RXRX cash_flow (annual, 2021-12-31) — Interest Paid Supplemental Data: 680000.00
RXRX cash_flow (annual, 2021-12-31) — Issuance Of Debt: 0.00
RXRX cash_flow (annual, 2021-12-31) — Long Term Debt Issuance: 0.00
RXRX cash_flow (annual, 2021-12-31) — Net Preferred Stock Issuance: 0.00
RXRX cash_flow (annual, 2021-12-31) — Operating Gains Losses: 827000.00
RXRX balance_sheet (annual, 2021-12-31) — Other Equity Adjustments: -126000.00
RXRX balance_sheet (annual, 2021-12-31) — Other Short Term Investments: 231446000.00
RXRX income_statement (annual, 2021-12-31) — Other Special Charges: 827000.00
RXRX cash_flow (annual, 2021-12-31) — Preferred Stock Issuance: 0.00
RXRX income_statement (annual, 2021-12-31) — Special Income Charges: -827000.00
RXRX income_statement (annual, 2021-12-31) — Total Unusual Items: -827000.00
RXRX income_statement (annual, 2021-12-31) — Total Unusual Items Excluding Goodwill: -827000.00
RXRX income_statement (annual, 2022-12-31) — +Operating Expense: 237133000.00
RXRX income_statement (annual, 2022-12-31) — +Total Revenue: 39681000.00
RXRX balance_sheet (annual, 2022-12-31) — Accounts Payable: 4586000.00
RXRX balance_sheet (annual, 2022-12-31) — Accounts Receivable: 0.00
RXRX balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -30115000.00
RXRX balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 1125360000.00
RXRX cash_flow (annual, 2022-12-31) — Asset Impairment Charge: 2806000.00
RXRX income_statement (annual, 2022-12-31) — Basic Average Shares: 175537487.00
RXRX income_statement (annual, 2022-12-31) — Basic EPS: -1.36
RXRX cash_flow (annual, 2022-12-31) — Beginning Cash Position: 295349000.00
RXRX cash_flow (annual, 2022-12-31) — Capital Expenditure: -37359000.00
RXRX balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 50372000.00
RXRX balance_sheet (annual, 2022-12-31) — Capital Stock: 2000.00
RXRX balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 549912000.00
RXRX balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 549912000.00
RXRX cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 154345000.00
RXRX cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: 193249000.00
RXRX cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: -83524000.00
RXRX cash_flow (annual, 2022-12-31) — Change In Account Payable: 1767000.00
RXRX cash_flow (annual, 2022-12-31) — Change In Accrued Expense: -54000.00
RXRX cash_flow (annual, 2022-12-31) — Change In Other Current Liabilities: -7110000.00
RXRX cash_flow (annual, 2022-12-31) — Change In Other Working Capital: 110320000.00
RXRX cash_flow (annual, 2022-12-31) — Change In Payable: 1767000.00
RXRX cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: 1713000.00
RXRX cash_flow (annual, 2022-12-31) — Change In Receivables: -2000.00
RXRX cash_flow (annual, 2022-12-31) — Change In Working Capital: 104921000.00
RXRX cash_flow (annual, 2022-12-31) — Changes In Cash: 264070000.00
RXRX balance_sheet (annual, 2022-12-31) — Common Stock: 2000.00
RXRX balance_sheet (annual, 2022-12-31) — Common Stock Equity: 485806000.00
RXRX cash_flow (annual, 2022-12-31) — Common Stock Issuance: 143711000.00
RXRX balance_sheet (annual, 2022-12-31) — Construction In Progress: 8747000.00
RXRX income_statement (annual, 2022-12-31) — Cost Of Revenue: 48275000.00
RXRX balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 12471000.00
RXRX balance_sheet (annual, 2022-12-31) — Current Assets: 569814000.00
RXRX balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 5952000.00
RXRX balance_sheet (annual, 2022-12-31) — Current Debt: 97000.00
RXRX balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 6049000.00
RXRX balance_sheet (annual, 2022-12-31) — Current Deferred Liabilities: 56726000.00
RXRX balance_sheet (annual, 2022-12-31) — Current Deferred Revenue: 56726000.00
RXRX balance_sheet (annual, 2022-12-31) — Current Liabilities: 100265000.00
RXRX cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 11756000.00
RXRX cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 11756000.00
RXRX income_statement (annual, 2022-12-31) — Diluted Average Shares: 175537487.00
RXRX income_statement (annual, 2022-12-31) — Diluted EPS: -1.36
RXRX income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -239476000.00
RXRX income_statement (annual, 2022-12-31) — EBIT: -239421000.00
RXRX income_statement (annual, 2022-12-31) — EBITDA: -227665000.00
RXRX cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: -307000.00
RXRX cash_flow (annual, 2022-12-31) — End Cash Position: 559112000.00
RXRX cash_flow (annual, 2022-12-31) — Financing Cash Flow: 154345000.00
RXRX cash_flow (annual, 2022-12-31) — Free Cash Flow: -120883000.00
RXRX balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: 0.00
RXRX income_statement (annual, 2022-12-31) — General And Administrative Expense: 81599000.00
RXRX balance_sheet (annual, 2022-12-31) — Goodwill: 801000.00
RXRX balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 2107000.00
RXRX balance_sheet (annual, 2022-12-31) — Gross PPE: 151562000.00
RXRX income_statement (annual, 2022-12-31) — Gross Profit: -8594000.00
RXRX income_statement (annual, 2022-12-31) — Interest Expense: 55000.00
RXRX income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 55000.00
RXRX income_statement (annual, 2022-12-31) — Interest Income: 6254000.00
RXRX income_statement (annual, 2022-12-31) — Interest Income Non Operating: 6254000.00
RXRX cash_flow (annual, 2022-12-31) — Interest Paid Supplemental Data: 55000.00
RXRX balance_sheet (annual, 2022-12-31) — Invested Capital: 486439000.00
RXRX cash_flow (annual, 2022-12-31) — Investing Cash Flow: 193249000.00
RXRX cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 143711000.00
RXRX cash_flow (annual, 2022-12-31) — Issuance Of Debt: 0.00
RXRX balance_sheet (annual, 2022-12-31) — Leases: 41872000.00
RXRX balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 44420000.00
RXRX balance_sheet (annual, 2022-12-31) — Long Term Debt: 536000.00
RXRX balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 44956000.00
RXRX cash_flow (annual, 2022-12-31) — Long Term Debt Issuance: 0.00
RXRX cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -90000.00
RXRX balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 20164000.00
RXRX cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: 0.00
RXRX cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 143711000.00
RXRX income_statement (annual, 2022-12-31) — Net Income: -239476000.00
RXRX income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -239476000.00
RXRX income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -239476000.00
RXRX income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -239476000.00
RXRX income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -239476000.00
RXRX cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -239476000.00
RXRX income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -239476000.00
RXRX cash_flow (annual, 2022-12-31) — Net Intangibles Purchase And Sale: -300000.00
RXRX income_statement (annual, 2022-12-31) — Net Interest Income: 6199000.00
RXRX cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: 230608000.00
RXRX cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -90000.00
RXRX cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -90000.00
RXRX income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: 6199000.00
RXRX balance_sheet (annual, 2022-12-31) — Net PPE: 121447000.00
RXRX cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -37059000.00
RXRX cash_flow (annual, 2022-12-31) — Net Preferred Stock Issuance: 0.00
RXRX balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 483699000.00
RXRX balance_sheet (annual, 2022-12-31) — Non Current Deferred Liabilities: 70261000.00
RXRX balance_sheet (annual, 2022-12-31) — Non Current Deferred Revenue: 70261000.00
RXRX balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Liabilities: 0.00
RXRX income_statement (annual, 2022-12-31) — Normalized EBITDA: -227665000.00
RXRX income_statement (annual, 2022-12-31) — Normalized Income: -239476000.00
RXRX cash_flow (annual, 2022-12-31) — Operating Cash Flow: -83524000.00
RXRX income_statement (annual, 2022-12-31) — Operating Income: -245727000.00
RXRX income_statement (annual, 2022-12-31) — Operating Revenue: 39681000.00
RXRX balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 191022864.00
RXRX balance_sheet (annual, 2022-12-31) — Other Current Assets: 15869000.00
RXRX balance_sheet (annual, 2022-12-31) — Other Current Borrowings: 97000.00
RXRX income_statement (annual, 2022-12-31) — Other Gand A: 81599000.00
RXRX income_statement (annual, 2022-12-31) — Other Income Expense: 52000.00
RXRX balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 1306000.00
RXRX cash_flow (annual, 2022-12-31) — Other Non Cash Items: 8560000.00
RXRX balance_sheet (annual, 2022-12-31) — Other Non Current Assets: 7920000.00
RXRX income_statement (annual, 2022-12-31) — Other Non Operating Income Expenses: 52000.00
RXRX income_statement (annual, 2022-12-31) — Other Operating Expenses: -162000.00
RXRX balance_sheet (annual, 2022-12-31) — Other Properties: 80779000.00
RXRX balance_sheet (annual, 2022-12-31) — Other Receivables: 2753000.00
RXRX balance_sheet (annual, 2022-12-31) — Other Short Term Investments: 0.00
RXRX balance_sheet (annual, 2022-12-31) — Payables: 4586000.00
RXRX balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 17057000.00
RXRX balance_sheet (annual, 2022-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 20433000.00
RXRX cash_flow (annual, 2022-12-31) — Preferred Stock Issuance: 0.00
RXRX income_statement (annual, 2022-12-31) — Pretax Income: -239476000.00
RXRX cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: 10724000.00
RXRX balance_sheet (annual, 2022-12-31) — Properties: 0.00
RXRX cash_flow (annual, 2022-12-31) — Purchase Of Business: 0.00
RXRX cash_flow (annual, 2022-12-31) — Purchase Of Intangibles: -300000.00
RXRX cash_flow (annual, 2022-12-31) — Purchase Of Investment: 0.00
RXRX cash_flow (annual, 2022-12-31) — Purchase Of PPE: -37059000.00
RXRX balance_sheet (annual, 2022-12-31) — Receivables: 2753000.00
RXRX income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 48275000.00
RXRX income_statement (annual, 2022-12-31) — Reconciled Depreciation: 11756000.00
RXRX cash_flow (annual, 2022-12-31) — Repayment Of Debt: -90000.00
RXRX income_statement (annual, 2022-12-31) — Research And Development: 155696000.00
RXRX balance_sheet (annual, 2022-12-31) — Restricted Cash: 1280000.00
RXRX balance_sheet (annual, 2022-12-31) — Retained Earnings: -639556000.00
RXRX cash_flow (annual, 2022-12-31) — Sale Of Business: 0.00
RXRX cash_flow (annual, 2022-12-31) — Sale Of Investment: 230608000.00
RXRX income_statement (annual, 2022-12-31) — Selling General And Administration: 81599000.00
RXRX balance_sheet (annual, 2022-12-31) — Share Issued: 191022864.00
RXRX income_statement (annual, 2022-12-31) — Special Income Charges: 0.00
RXRX cash_flow (annual, 2022-12-31) — Stock Based Compensation: 27909000.00
RXRX balance_sheet (annual, 2022-12-31) — Stockholders Equity: 485806000.00
RXRX balance_sheet (annual, 2022-12-31) — Tangible Book Value: 483699000.00
RXRX income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
RXRX income_statement (annual, 2022-12-31) — Tax Provision: 0.00
RXRX income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.00
RXRX balance_sheet (annual, 2022-12-31) — Total Assets: 701288000.00
RXRX balance_sheet (annual, 2022-12-31) — Total Capitalization: 486342000.00
RXRX balance_sheet (annual, 2022-12-31) — Total Debt: 51005000.00
RXRX balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 485806000.00
RXRX income_statement (annual, 2022-12-31) — Total Expenses: 285408000.00
RXRX balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 215482000.00
RXRX balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 131474000.00
RXRX balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 115217000.00
RXRX income_statement (annual, 2022-12-31) — Total Operating Income As Reported: -245727000.00
RXRX income_statement (annual, 2022-12-31) — Total Unusual Items: 0.00
RXRX income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: 0.00
RXRX balance_sheet (annual, 2022-12-31) — Working Capital: 469549000.00
RXRX income_statement (annual, 2023-12-31) — +Operating Expense: 351349000.00
RXRX income_statement (annual, 2023-12-31) — +Total Revenue: 43876000.00
RXRX balance_sheet (annual, 2023-12-31) — Accounts Payable: 3953000.00
RXRX balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -44872000.00
RXRX balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 1431056000.00
RXRX cash_flow (annual, 2023-12-31) — Asset Impairment Charge: 1188000.00
RXRX income_statement (annual, 2023-12-31) — Basic Average Shares: 207853702.00
RXRX income_statement (annual, 2023-12-31) — Basic EPS: -1.58
RXRX cash_flow (annual, 2023-12-31) — Beginning Cash Position: 559112000.00
RXRX cash_flow (annual, 2023-12-31) — Capital Expenditure: -12552000.00
RXRX balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 49530000.00
RXRX balance_sheet (annual, 2023-12-31) — Capital Stock: 2000.00
RXRX balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 391565000.00
RXRX balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 391565000.00
RXRX cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: 140133000.00
RXRX cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: -10228000.00
RXRX cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: -287780000.00
RXRX cash_flow (annual, 2023-12-31) — Change In Account Payable: -987000.00
RXRX cash_flow (annual, 2023-12-31) — Change In Accrued Expense: 9424000.00
RXRX cash_flow (annual, 2023-12-31) — Change In Other Current Liabilities: -9862000.00
RXRX cash_flow (annual, 2023-12-31) — Change In Other Working Capital: -41076000.00
RXRX cash_flow (annual, 2023-12-31) — Change In Payable: -987000.00
RXRX cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 8437000.00
RXRX cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: 6000000.00
RXRX cash_flow (annual, 2023-12-31) — Change In Receivables: -7756000.00
RXRX cash_flow (annual, 2023-12-31) — Change In Working Capital: -44257000.00
RXRX cash_flow (annual, 2023-12-31) — Changes In Cash: -157875000.00
RXRX balance_sheet (annual, 2023-12-31) — Common Stock: 2000.00
RXRX balance_sheet (annual, 2023-12-31) — Common Stock Equity: 463436000.00
RXRX cash_flow (annual, 2023-12-31) — Common Stock Issuance: 128093000.00
RXRX balance_sheet (annual, 2023-12-31) — Construction In Progress: 3231000.00
RXRX income_statement (annual, 2023-12-31) — Cost Of Revenue: 42587000.00
RXRX balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 23747000.00
RXRX balance_sheet (annual, 2023-12-31) — Current Assets: 438137000.00
RXRX balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 6116000.00
RXRX balance_sheet (annual, 2023-12-31) — Current Debt: 41000.00
RXRX balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 6157000.00
RXRX balance_sheet (annual, 2023-12-31) — Current Deferred Liabilities: 36426000.00
RXRX balance_sheet (annual, 2023-12-31) — Current Deferred Revenue: 36426000.00
RXRX balance_sheet (annual, 2023-12-31) — Current Liabilities: 93171000.00
RXRX cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 24402000.00
RXRX cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 24402000.00
RXRX income_statement (annual, 2023-12-31) — Diluted Average Shares: 207853702.00
RXRX income_statement (annual, 2023-12-31) — Diluted EPS: -1.58
RXRX income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -328066000.00
RXRX income_statement (annual, 2023-12-31) — EBIT: -332031000.00
RXRX income_statement (annual, 2023-12-31) — EBITDA: -307629000.00
RXRX cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: 188000.00
RXRX cash_flow (annual, 2023-12-31) — End Cash Position: 401425000.00
RXRX cash_flow (annual, 2023-12-31) — Financing Cash Flow: 140133000.00
RXRX cash_flow (annual, 2023-12-31) — Free Cash Flow: -300332000.00
RXRX cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of Business: 0.00
RXRX balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: 0.00
RXRX income_statement (annual, 2023-12-31) — General And Administrative Expense: 110822000.00
RXRX balance_sheet (annual, 2023-12-31) — Goodwill: 52056000.00
RXRX balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 88499000.00
RXRX balance_sheet (annual, 2023-12-31) — Gross PPE: 165045000.00
RXRX income_statement (annual, 2023-12-31) — Gross Profit: 1289000.00
RXRX income_statement (annual, 2023-12-31) — Interest Expense: 97000.00
RXRX income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 97000.00
RXRX income_statement (annual, 2023-12-31) — Interest Income: 19116000.00
RXRX income_statement (annual, 2023-12-31) — Interest Income Non Operating: 19116000.00
RXRX cash_flow (annual, 2023-12-31) — Interest Paid Supplemental Data: 96000.00
RXRX balance_sheet (annual, 2023-12-31) — Invested Capital: 464578000.00
RXRX cash_flow (annual, 2023-12-31) — Investing Cash Flow: -10228000.00
RXRX cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 128093000.00
RXRX balance_sheet (annual, 2023-12-31) — Leases: 45929000.00
RXRX balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 43414000.00
RXRX balance_sheet (annual, 2023-12-31) — Long Term Debt: 1101000.00
RXRX balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 44515000.00
RXRX cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -766000.00
RXRX balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 22126000.00
RXRX cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: 1844000.00
RXRX cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 128093000.00
RXRX income_statement (annual, 2023-12-31) — Net Income: -328066000.00
RXRX income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -328066000.00
RXRX income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -328066000.00
RXRX income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -328066000.00
RXRX income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -328066000.00
RXRX cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -328066000.00
RXRX income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -328066000.00
RXRX cash_flow (annual, 2023-12-31) — Net Intangibles Purchase And Sale: -597000.00
RXRX income_statement (annual, 2023-12-31) — Net Interest Income: 19019000.00
RXRX cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: 480000.00
RXRX cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -766000.00
RXRX cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -766000.00
RXRX income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: 19019000.00
RXRX balance_sheet (annual, 2023-12-31) — Net PPE: 120173000.00
RXRX cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -11955000.00
RXRX balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 374937000.00
RXRX balance_sheet (annual, 2023-12-31) — Non Current Deferred Assets: 0.00
RXRX balance_sheet (annual, 2023-12-31) — Non Current Deferred Liabilities: 52577000.00
RXRX balance_sheet (annual, 2023-12-31) — Non Current Deferred Revenue: 51238000.00
RXRX balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Assets: 0.00
RXRX balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Liabilities: 1339000.00
RXRX income_statement (annual, 2023-12-31) — Normalized EBITDA: -307629000.00
RXRX income_statement (annual, 2023-12-31) — Normalized Income: -328066000.00
RXRX cash_flow (annual, 2023-12-31) — Operating Cash Flow: -287780000.00
RXRX income_statement (annual, 2023-12-31) — Operating Income: -350060000.00
RXRX income_statement (annual, 2023-12-31) — Operating Revenue: 43876000.00
RXRX balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 234270384.00
RXRX balance_sheet (annual, 2023-12-31) — Other Current Assets: 40247000.00
RXRX balance_sheet (annual, 2023-12-31) — Other Current Borrowings: 41000.00
RXRX income_statement (annual, 2023-12-31) — Other Gand A: 110822000.00
RXRX income_statement (annual, 2023-12-31) — Other Income Expense: -1087000.00
RXRX balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 36443000.00
RXRX cash_flow (annual, 2023-12-31) — Other Non Cash Items: 5450000.00
RXRX balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 6890000.00
RXRX income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: -1087000.00
RXRX income_statement (annual, 2023-12-31) — Other Operating Expenses: -699000.00
RXRX balance_sheet (annual, 2023-12-31) — Other Properties: 93759000.00
RXRX balance_sheet (annual, 2023-12-31) — Other Receivables: 3094000.00
RXRX balance_sheet (annual, 2023-12-31) — Payables: 3953000.00
RXRX balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 27700000.00
RXRX balance_sheet (annual, 2023-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 22888000.00
RXRX income_statement (annual, 2023-12-31) — Pretax Income: -332128000.00
RXRX cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 12806000.00
RXRX balance_sheet (annual, 2023-12-31) — Properties: 0.00
RXRX cash_flow (annual, 2023-12-31) — Purchase Of Business: 0.00
RXRX cash_flow (annual, 2023-12-31) — Purchase Of Intangibles: -597000.00
RXRX cash_flow (annual, 2023-12-31) — Purchase Of Investment: 0.00
RXRX cash_flow (annual, 2023-12-31) — Purchase Of PPE: -11955000.00
RXRX balance_sheet (annual, 2023-12-31) — Receivables: 3094000.00
RXRX income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 42587000.00
RXRX income_statement (annual, 2023-12-31) — Reconciled Depreciation: 24402000.00
RXRX cash_flow (annual, 2023-12-31) — Repayment Of Debt: -766000.00
RXRX income_statement (annual, 2023-12-31) — Research And Development: 241226000.00
RXRX balance_sheet (annual, 2023-12-31) — Restricted Cash: 3231000.00
RXRX balance_sheet (annual, 2023-12-31) — Retained Earnings: -967622000.00
RXRX cash_flow (annual, 2023-12-31) — Sale Of Business: 1844000.00
RXRX cash_flow (annual, 2023-12-31) — Sale Of Investment: 480000.00
RXRX income_statement (annual, 2023-12-31) — Selling General And Administration: 110822000.00
RXRX balance_sheet (annual, 2023-12-31) — Share Issued: 234270384.00
RXRX income_statement (annual, 2023-12-31) — Special Income Charges: 0.00
RXRX cash_flow (annual, 2023-12-31) — Stock Based Compensation: 53503000.00
RXRX balance_sheet (annual, 2023-12-31) — Stockholders Equity: 463436000.00
RXRX balance_sheet (annual, 2023-12-31) — Tangible Book Value: 374937000.00
RXRX income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 0.00
RXRX income_statement (annual, 2023-12-31) — Tax Provision: -4062000.00
RXRX income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.01
RXRX balance_sheet (annual, 2023-12-31) — Total Assets: 653699000.00
RXRX balance_sheet (annual, 2023-12-31) — Total Capitalization: 464537000.00
RXRX balance_sheet (annual, 2023-12-31) — Total Debt: 50672000.00
RXRX balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 463436000.00
RXRX income_statement (annual, 2023-12-31) — Total Expenses: 393936000.00
RXRX balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 190263000.00
RXRX balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 215562000.00
RXRX balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 97092000.00
RXRX income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -350060000.00
RXRX income_statement (annual, 2023-12-31) — Total Unusual Items: 0.00
RXRX income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: 0.00
RXRX balance_sheet (annual, 2023-12-31) — Working Capital: 344966000.00
RXRX balance_sheet (quarterly, 2024-09-30) — Accumulated Depreciation: -56467000.00
RXRX balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 1712000.00
RXRX balance_sheet (quarterly, 2024-09-30) — Leases: 47041000.00
RXRX balance_sheet (quarterly, 2024-09-30) — Machinery Furniture Equipment: 25370000.00
RXRX balance_sheet (quarterly, 2024-09-30) — Properties: 0.00
RXRX cash_flow (quarterly, 2024-09-30) — Sale Of Business: 0.00
RXRX income_statement (annual, 2024-12-31) — +Operating Expense: 492254000.00
RXRX income_statement (annual, 2024-12-31) — +Total Revenue: 58488000.00
RXRX balance_sheet (annual, 2024-12-31) — Accounts Payable: 21613000.00
RXRX balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -62671000.00
RXRX balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -62671000.00
RXRX balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 2473698000.00
RXRX cash_flow (annual, 2024-12-31) — Asset Impairment Charge: 108000.00
RXRX income_statement (annual, 2024-12-31) — Basic Average Shares: 274207146.00
RXRX income_statement (annual, 2024-12-31) — Basic EPS: -1.69
RXRX cash_flow (annual, 2024-12-31) — Beginning Cash Position: 401425000.00
RXRX cash_flow (annual, 2024-12-31) — Capital Expenditure: -17045000.00
RXRX balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 81045000.00
RXRX balance_sheet (annual, 2024-12-31) — Capital Stock: 4000.00
RXRX balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 594350000.00
RXRX balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 594350000.00
RXRX cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: 304120000.00
RXRX cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: 260059000.00
RXRX cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: -359174000.00
RXRX cash_flow (annual, 2024-12-31) — Change In Account Payable: 6435000.00
RXRX cash_flow (annual, 2024-12-31) — Change In Accrued Expense: 5255000.00
RXRX cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: -15582000.00
RXRX cash_flow (annual, 2024-12-31) — Change In Other Working Capital: -28038000.00
RXRX cash_flow (annual, 2024-12-31) — Change In Payable: 6435000.00
RXRX cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: 11690000.00
RXRX cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: -8757000.00
RXRX cash_flow (annual, 2024-12-31) — Change In Receivables: -6071000.00
RXRX cash_flow (annual, 2024-12-31) — Change In Working Capital: -46758000.00
RXRX cash_flow (annual, 2024-12-31) — Changes In Cash: 205005000.00
RXRX balance_sheet (annual, 2024-12-31) — Common Stock: 4000.00
RXRX balance_sheet (annual, 2024-12-31) — Common Stock Equity: 1034782000.00
RXRX cash_flow (annual, 2024-12-31) — Common Stock Issuance: 300417000.00
RXRX balance_sheet (annual, 2024-12-31) — Construction In Progress: 2714000.00
RXRX balance_sheet (quarterly, 2024-12-31) — Construction In Progress: 2714000.00
RXRX income_statement (annual, 2024-12-31) — Cost Of Revenue: 45238000.00
RXRX balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 31019000.00
RXRX balance_sheet (annual, 2024-12-31) — Current Assets: 714269000.00
RXRX balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 13795000.00
RXRX balance_sheet (annual, 2024-12-31) — Current Debt: 8425000.00
RXRX balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 22220000.00
RXRX balance_sheet (annual, 2024-12-31) — Current Deferred Liabilities: 61767000.00
RXRX balance_sheet (annual, 2024-12-31) — Current Deferred Revenue: 61767000.00
RXRX balance_sheet (annual, 2024-12-31) — Current Liabilities: 187472000.00
RXRX cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 36494000.00